Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.

Stone LA, Cutter GR, Fisher E, Richert N, McCartin J, Ohayon J, Bash C, McFarland H.

J Neuroimaging. 2016 May;26(3):296-302. doi: 10.1111/jon.12321. Epub 2015 Dec 21.

PMID:
26686343
2.

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.

Mult Scler. 2016 Aug;22(9):1174-83. doi: 10.1177/1352458515615225. Epub 2015 Nov 12.

PMID:
26564995
3.

Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D.

AJNR Am J Neuroradiol. 2016 Mar;37(3):394-401. doi: 10.3174/ajnr.A4539. Epub 2015 Nov 12.

4.

MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.

Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BM, Barkhof F, Killestein J; Dutch-Belgian Natalizumab-associated PML study group.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):879-84. doi: 10.1136/jnnp-2015-311411. Epub 2015 Sep 14.

PMID:
26369555
5.

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.

Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.

J Neurovirol. 2015 Dec;21(6):637-44. doi: 10.1007/s13365-015-0316-4. Epub 2015 Mar 14.

6.

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N.

Ann Clin Transl Neurol. 2014 Oct;1(10):755-64. doi: 10.1002/acn3.114. Epub 2014 Oct 9.

7.

Diffuse and focal corticospinal tract disease and its impact on patient disability in multiple sclerosis.

Tovar-Moll F, Evangelou IE, Chiu AW, Auh S, Chen C, Ehrmantraut M, Ohayon JM, Richert N, Bagnato F.

J Neuroimaging. 2015 Mar-Apr;25(2):200-206. doi: 10.1111/jon.12171. Epub 2014 Oct 16.

8.

MRI pattern in asymptomatic natalizumab-associated PML.

Wattjes MP, Vennegoor A, Steenwijk MD, de Vos M, Killestein J, van Oosten BW, Mostert J, Siepman DA, Moll W, van Golde AE, Frequin ST, Richert ND, Barkhof F.

J Neurol Neurosurg Psychiatry. 2015 Jul;86(7):793-8. doi: 10.1136/jnnp-2014-308630. Epub 2014 Sep 9.

PMID:
25205744
9.

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.

Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.

Mult Scler. 2013 Dec;19(14):1826-40. doi: 10.1177/1352458513510224. Epub 2013 Nov 5. Review.

PMID:
24192217
10.

Evolution of tumefactive lesions in multiple sclerosis: a 12-year study with serial imaging in a single patient.

Ikonomidou VN, Richert ND, Vortmeyer A, Tovar-Moll F, Bielekova B, Cook NE, Duyn JH, Bagnato F.

Mult Scler. 2013 Oct;19(11):1539-43. doi: 10.1177/1352458513498124.

11.

CNS vasculitis in a patient with MS on daclizumab monotherapy.

Ohayon J, Oh U, Richert N, Martin J, Vortmeyer A, McFarland H, Bielekova B.

Neurology. 2013 Jan 29;80(5):453-7. doi: 10.1212/WNL.0b013e31827f0f42. Epub 2013 Jan 9.

12.

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.

Ann Neurol. 2012 Nov;72(5):779-87. doi: 10.1002/ana.23676.

PMID:
23280794
13.

Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Campbell Z, Sahm D, Donohue K, Jamison J, Davis M, Pellicano C, Auh S, Ohayon J, Frank JA, Richert N, Bagnato F.

Neurology. 2012 May 8;78(19):1493-9. doi: 10.1212/WNL.0b013e3182553bd2. Epub 2012 Apr 25.

14.

Does one guideline fit all?

Richert ND, Kryscio RJ.

Neurology. 2011 Dec 13;77(24):2080-1. doi: 10.1212/WNL.0b013e31823d76ba. Epub 2011 Nov 16. No abstract available.

PMID:
22094478
15.

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Bielekova B, Richert N, Herman ML, Ohayon J, Waldmann TA, McFarland H, Martin R, Blevins G.

Neurology. 2011 Nov 22;77(21):1877-86. doi: 10.1212/WNL.0b013e318239f7ef. Epub 2011 Nov 9.

16.

Lesions by tissue specific imaging characterize multiple sclerosis patients with more advanced disease.

Bagnato F, Ikonomidou VN, van Gelderen P, Auh S, Hanafy J, Cantor FK, Ohayon J, Richert N, Duyn J.

Mult Scler. 2011 Dec;17(12):1424-31. doi: 10.1177/1352458511414601. Epub 2011 Jul 29.

PMID:
21803873
17.

Swabbing firearms for handler's DNA.

Richert NJ.

J Forensic Sci. 2011 Jul;56(4):972-5. doi: 10.1111/j.1556-4029.2011.01766.x. Epub 2011 Apr 6.

PMID:
21470231
18.

Translocator protein PET imaging for glial activation in multiple sclerosis.

Oh U, Fujita M, Ikonomidou VN, Evangelou IE, Matsuura E, Harberts E, Fujimura Y, Richert ND, Ohayon J, Pike VW, Zhang Y, Zoghbi SS, Innis RB, Jacobson S.

J Neuroimmune Pharmacol. 2011 Sep;6(3):354-61. doi: 10.1007/s11481-010-9243-6. Epub 2010 Sep 25. Erratum in: J Neuroimmune Pharmacol. 2011 Sep;6(3):434. Fujimura, Yota [added]; Richert, Nancy D [added].

19.

Ring and nodular multiple sclerosis lesions: a retrospective natural history study.

Davis M, Auh S, Riva M, Richert ND, Frank JA, McFarland HF, Bagnato F.

Neurology. 2010 Mar 9;74(10):851-6. doi: 10.1212/WNL.0b013e3181d31df5.

20.

Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Bielekova B, Richert N, Howard T, Packer AN, Blevins G, Ohayon J, McFarland HF, Stürzebecher CS, Martin R.

Mult Scler. 2009 Oct;15(10):1206-14. doi: 10.1177/1352458509345903. Epub 2009 Sep 23.

21.

Tissue-specific imaging is a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage.

Riva M, Ikonomidou VN, Ostuni JJ, van Gelderen P, Auh S, Ohayon JM, Tovar-Moll F, Richert ND, Duyn JH, Bagnato F.

AJNR Am J Neuroradiol. 2009 Aug;30(7):1394-401. doi: 10.3174/ajnr.A1573. Epub 2009 Apr 30.

22.

Thalamic involvement and its impact on clinical disability in patients with multiple sclerosis: a diffusion tensor imaging study at 3T.

Tovar-Moll F, Evangelou IE, Chiu AW, Richert ND, Ostuni JL, Ohayon JM, Auh S, Ehrmantraut M, Talagala SL, McFarland HF, Bagnato F.

AJNR Am J Neuroradiol. 2009 Aug;30(7):1380-6. doi: 10.3174/ajnr.A1564. Epub 2009 Apr 15.

23.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

24.

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, McFarland H, Jacobson S.

Arch Neurol. 2009 Apr;66(4):471-9. doi: 10.1001/archneurol.2009.16.

25.

Visualizing the cause of gray matter atrophy in multiple sclerosis.

Richert ND, Kraft E, Stüve O.

Arch Neurol. 2009 Feb;66(2):159-60. doi: 10.1001/archneurol.2008.563. No abstract available.

PMID:
19204151
26.

Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.

Chiu AW, Richert N, Ehrmantraut M, Ohayon J, Gupta S, Bomboi G, Gaindh D, Cantor FK, Frank JA, McFarland HF, Bagnato F.

Arch Neurol. 2009 Jan;66(1):39-43. doi: 10.1001/archneur.66.1.noc80047. Epub 2008 Nov 10.

PMID:
19001157
27.

The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

Gaindh D, Jeffries N, Ohayon J, Richert ND, Pellicano C, Frank JA, McFarland H, Bagnato F.

Expert Opin Biol Ther. 2008 Dec;8(12):1823-9. doi: 10.1517/14712590802510629 .

28.

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DA.

Arch Neurol. 2008 Aug;65(8):1044-51. doi: 10.1001/archneurol.65.8.noc80042. Epub 2008 Jun 9.

29.

A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.

Chiu AW, Ehrmantraut M, Richert ND, Ikonomidou VN, Pellegrini S, McFarland HF, Frank JA, Bagnato F.

Clin Exp Immunol. 2007 Oct;150(1):61-7. Epub 2007 Jul 30.

30.

Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis.

Richert ND, Howard T, Frank JA, Stone R, Ostuni J, Ohayon J, Bash C, McFarland HF.

Neurology. 2006 Feb 28;66(4):551-6.

PMID:
16505310
31.

Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.

Gupta S, Solomon JM, Tasciyan TA, Cao MM, Stone RD, Ostuni JL, Ohayon JM, Muraro PA, Frank JA, Richert ND, McFarland HF, Bagnato F.

Mult Scler. 2005 Dec;11(6):658-68.

PMID:
16320725
32.

MRI as a marker for disease heterogeneity in multiple sclerosis.

Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF.

Neurology. 2005 Oct 11;65(7):1071-6.

PMID:
16217061
33.

Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.

Bagnato F, Gupta S, Richert ND, Stone RD, Ohayon JM, Frank JA, McFarland HF.

Arch Neurol. 2005 Nov;62(11):1684-8. Epub 2005 Sep 12.

PMID:
16157739
34.

Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis.

Morgen K, Crawford AL, Stone RD, Martin R, Richert ND, Frank JA, McFarland HF.

Mult Scler. 2005 Apr;11(2):146-8.

PMID:
15794386
35.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, Frank JA, Würfel J, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8. Epub 2004 May 25. Erratum in: Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17565.

36.

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF.

Neurology. 2004 Mar 9;62(5):719-25.

PMID:
15007120
37.

Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.

Bagnato F, Jeffries N, Richert ND, Stone RD, Ohayon JM, McFarland HF, Frank JA.

Brain. 2003 Aug;126(Pt 8):1782-9. Epub 2003 Jun 23.

PMID:
12821527
38.

Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences.

Leigh R, Ostuni J, Pham D, Goldszal A, Lewis BK, Howard T, Richert N, McFarland H, Frank JA.

Mult Scler. 2002 Oct;8(5):420-9.

PMID:
12356210
39.

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.

Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA.

Neurology. 2002 Sep 10;59(5):688-94.

PMID:
12221158
40.

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

Richert ND.

Neurology. 2002 May 14;58(9):1440-1; author reply 1441-2. No abstract available.

PMID:
12011306
41.

Proton MR spectroscopic imaging in multiple sclerosis.

Tedeschi G, Bonavita S, McFarland HF, Richert N, Duyn JH, Frank JA.

Neuroradiology. 2002 Jan;44(1):37-42.

PMID:
11942498
42.

A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.

Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T.

Mult Scler. 2002 Feb;8(1):24-9.

PMID:
11936485
43.

Comparison of methods for obtaining longitudinal whole-brain magnetization transfer measurements.

Ostuni JL, Richert N, Wisniewski R, Lewis BK, Howard T, Patel J, Frank JA.

J Magn Reson Imaging. 2002 Jan;15(1):8-15.

PMID:
11793451
44.

Ring-enchancement in multiple sclerosis: marker of disease severity.

Morgen K, Jeffries NO, Stone R, Martin R, Richert ND, Frank JA, McFarland HF.

Mult Scler. 2001 Jun;7(3):167-71.

PMID:
11475440
45.

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.

Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA.

Mult Scler. 2001 Feb;7(1):49-58.

PMID:
11321194
46.

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand.

Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R.

Nat Med. 2000 Oct;6(10):1167-75. Erratum in: Nat Med 2000 Dec;6(12):1412.

PMID:
11017150
47.

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.

Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA.

Mult Scler. 2000 Apr;6(2):86-90.

PMID:
10773853
48.

Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study.

Bagnato F, Tancredi A, Richert N, Gasperini C, Bastianello S, Bash C, McFarland H, Pozzilli C, Frank JA.

Mult Scler. 2000 Feb;6(1):43-9.

PMID:
10694845
49.
50.

Magnetization transfer imaging to monitor clinical trials in multiple sclerosis.

Richert ND, Frank JA.

Neurology. 1999;53(5 Suppl 3):S29-32. Review.

PMID:
10496208

Supplemental Content

Loading ...
Support Center